To equip users with a complete next generation sequencing (NGS) solution from sample to answer, global genomics leader Integrated DNA Technologies (IDT), together with Hamilton (Hamilton Company and Hamilton Bonaduz AG), a global leader in precision laboratory automation, are entering into a strategic partnership to automate comprehensive genomic profiling (CGP) workflows across IDT’s wide range of customizable NGS research components and assay solutions, empowering labs with an efficient path to accelerate important genomic discoveries.

IDT’s partnership with Hamilton marks a global agreement to develop automation scripts for xGen™ and Archer™ NGS products from IDT for use on Hamilton’s Microlab® STAR™ and NIMBUS® liquid handling platforms. This provides labs worldwide with market-differentiated capabilities from IDT’s diverse NGS portfolio to identify key biomarkers critical for cancer research and other genomic applications.

“At IDT, we believe that innovation happens when scientists have the freedom to design workflows that fit their research needs,” said IDT President Ajay Gannerkote. “By pairing IDT’s flexible NGS solutions with Hamilton’s automation expertise, we’re removing constraints that may arise from one-size-fits-all approaches so labs can consistently and reliably accelerate their discoveries with confidence, precision and speed, at whatever scale their work demands.”

“Hamilton is proud to partner with IDT to bring flexible, automation-ready NGS workflows to the global research community,” said Michael Mouradian, Hamilton Vice President of Scientific Strategy and Market Development. “By combining Hamilton’s precision engineering and trusted liquid handling platforms with IDT’s innovative assay solutions, we are enabling laboratories to achieve greater scalability, consistency, and efficiency in their genomic discoveries. The partnership reflects Hamilton’s commitment to empowering scientists with solutions that accelerate breakthroughs in research and beyond.”

This global agreement underscores IDT’s mission to provide modular, scalable solutions that adapt to evolving research demands, while Hamilton’s automation expertise ensures precision and consistency at every step. For researchers, this can result in less time spent on manual processes and more time generating actionable data, driving progress in cancer research and beyond. The partnership also bolsters IDT’s NGS sample-to-report assay offerings comprised of platform-agnostic solutions designed to fit all lab’s solid tumor and blood cancer research needs.